These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Completed, but no date Terminated 2004-004620-12 Assessment of normal release morphine in the management of dyspnoea bad-data
Ongoing 2004-004707-38 A multicentre randomised phase II clinical trial comparing oxaliplatin (Eloxatin), capecitabine (Xeloda) and pre-operative radiotherapy with or without cetuximab followed by total mesorectal excision ... not-yet-due
Ongoing 2005-001660-31 A Prospective Randomized Controlled Trial of Morphine versus Oxycodone for Cancer Pain: Genetic Determinants of Response to Opioids. not-yet-due
Exempt 2005-002027-13 A phase I/II study of docetaxel plus prednisolone plus diethylstilbestrol plus aspirin in androgen-independent prostate cancer not-yet-due
Exempt, with results 2005-002715-24 TARGET Trial: A Phase I-II dose finding and early efficacy study of combination therapy with erlotinib (tarceva), gemcitabine, bevacizumab (avastin) and capecitabine in advanced pancreatic cancer. not-yet-due
Ongoing 2005-002736-10 Open, Randomised Phase II Study Assessing The Toxicity And Efficacy Of Platinum-Based Chemotherapy With Vitamin Supplementation In The Treatment Of Lung Cancer not-yet-due
Exempt, with results 2005-002801-22 Carboplatin Plus Xeloda Followed By Maintenance Xeloda (CARBOX) not-yet-due
Ongoing 2005-003795-37 Response to Parenteral Morphine and Oxycodone in Acute Pain. not-yet-due
Reported results 2005-004505-29 Phase II clinical trial of capecitabine and oxaliplatin plus bevacizumab as neoadjuvant treatment for patients with previously untreated unresectable liver-only metastases from colorectal cancer 2015-02-10 due-trials
Ongoing 2005-004508-35 THE USE OF PET/CT SCANNING TO ASSESS EARLY RESPONDERS TO TARCEVA (ERLOTINIB): A PHASE II STUDY not-yet-due
Ongoing 2005-006018-16 A Randomised Phase III Trial Of Low Dose DailyDexamethasone Versus Intermittent Dexamethasone Versus Prednisolone In Hormone Refractory Prostate Cancer not-yet-due
Completed, but no date Terminated 2006-000492-16 A Phase II, Single-Centre, Randomised, Controlled, Open-Label Clinical Trial to Compare the Efficacy and Safety of Three Therapeutic Interventions on the Treatment of Hypothalamic Obesity due to Child... bad-data
Ongoing 2006-000810-18 A Randomised Study to Investigate the Effectiveness of Acupuncture for the Relief of Dyspnoea in Patients with Non-Small Cell Lung Cancer not-yet-due
Not reported Terminated 2006-003844-41 Feasibility study of R-CHOP plus bevacizumab in patients with diffuse large B cell lymphoma (DLBCL) 2010-06-15 due-trials
Not reported 2006-004282-34 A phase II study of bethanechol chloride to treat pseudomembranous candidosis in cancer patients with salivary gland dysfunction. 2010-09-01 due-trials
Exempt Terminated 2006-004822-97 A Phase I / II Trial to Evaluate the Combination of Infliximab and Sorafenib in the Treatment of Renal Cell Carcinoma 2009-09-14 not-yet-due
Reported results Terminated 2006-006073-24 CINATRA: Chromosomal Instability and Anti-Tubulin Response Assessment: A Phase II Study of Epothilone B in Metastatic Colon Carcinoma in patients with Microsatellite Instability or Chromosomal Instabi... 2011-04-11 due-trials
Ongoing 2006-006615-80 A Pilot Study in Metastatic Advanced Thyroid Cancer Evaluating the Safety and Efficacy of Sorafenib not-yet-due
Ongoing 2007-000805-32 AN INVESTIGATION INTO THE ROLE OF PARACETAMOL (ACETAMINOPHEN) AT STEP 3 OF THE WHO ANALGESIC LADDER not-yet-due
Ongoing 2007-003877-21 Trial of Perioperative Endocrine Therapy - Individualising Care (POETIC) not-yet-due
Ongoing 2007-005976-15 A randomised open-labelled multicentre trial of the efficacy of epirubicin, oxaliplatin and capecitabine (EOX) with or without panitumumab in previously untreated advanced oesophago-gastric cancer (RE... not-yet-due
Ongoing, reported early 2008-000517-30 A multicentre randomised phase II clinical study of UFT/leucovorin (LV), radiotherapy with or without cetuximab following induction gemcitabine plus capecitabine in patients with locally advanced panc... not-yet-due
Not reported Terminated 2008-000524-82 MESH: A Non-Randomised Phase II Trial of Methotrexate in Metastatic Colorectal Cancer with MSH2 Deficiency 2012-04-16 due-trials
Ongoing, reported early 2008-004499-38 A randomised double-blind placebo-controlled trial of the safety and efficacy of ethosuximide 250mg capsules for the management of chemotherapy-induced painful peripheral neuropathy. not-yet-due
Exempt 2008-008676-13 A Phase II Study Of Sunitinib And Low Dose Metronomic Cyclophosphamide In Advanced Renal Cell Cancer not-yet-due
Reported results 2009-012945-49 A Phase II Trial of Nilotinib in the Treatment of Patients with c-KIT Mutated Advanced Acral and Mucosal Melanoma (NICAM) 2016-12-12 due-trials
Ongoing 2010-021163-33 A Phase II Trial of Cediranib in the Treatment of Patients with Alveolar Soft Part Sarcoma (CASPS). not-yet-due
Ongoing 2010-021412-42 Prospective randomised controlled trial to investigate the effectiveness of inhalers for the relief of breathlessness in patients with lung cancer and COPD not-yet-due
Ongoing 2010-022416-40 A Translational, proof of the concept, study Of Pre-operative Pazopanib in treatment-naive patients with resectable soft tissue Sarcomas (TOPPS) not-yet-due
Ongoing 2011-000601-49 TOPARP: Phase II Trial of Olaparib in Patients with Advanced Castration Resistant Prostate Cancer. not-yet-due
Ongoing 2011-001793-26 A Phase II Trial of Metformin and Axitinib in BRAF Mutated Advanced Melanoma not-yet-due
Ongoing 2011-003718-18 Proof-of-concept study of AZD 4547 in patients with FGFR1 or FGFR2 amplified tumours not-yet-due
Ongoing 2011-004146-18 Cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) versus gemcitabine, cisplatin and methyl prednisolone (GEM-P) in the first line treatment Of T-cell Lymphoma, a multicentre randomis... not-yet-due
Ongoing 2011-004562-16 A Phase II Study of Axitinib in Patients with Metastatic Renal Cell Cancer Unsuitable for Nephrectomy not-yet-due
Ongoing 2012-002620-32 A randomised phase II study comparing LEnalidomide plus rituximab, GEmcitabine and methylprednisolone (LR-GEM) to rituximab, gemcitabine, methylprednisolone and cisplatiN (R-GEM-P) in second-line trea... not-yet-due
Exempt 2012-003896-20 TAX-TORC: A Phase I multi-centre trial of the combination of AZD2014 (dual TORC1 and TORC2 inhibitor) and weekly paclitaxel in patients with solid tumours 2017-11-15 not-yet-due
Ongoing 2012-004211-31 Randomised double-blind controlled phase II trial of Tocovid SupraBio in combination with pentoxifylline (PTX) in patients suffering long-term adverse effects of radiotherapy for pelvic cancer not-yet-due
Ongoing 2013-000293-29 A prospective, multi-centre, open label, non-randomised two stage phase II clinical trial evaluating the efficacy of abiraterone in patients with epithelial ovarian (including fallopian tube and prima... not-yet-due
Ongoing 2013-001949-13 An International Multicentre Open Label Randomised Phase II Advanced Anal Cancer Trial Comparing Cisplatin plus 5-fluorouracil versus Carboplatin plus Weekly Paclitaxel in Patients with Inoperable Loc... not-yet-due
Ongoing 2013-004055-20 A phase II randomised trial of biomarkers to assess (dose-) response in patients with metastatic castration resistant prostate cancer treated with radium-223. not-yet-due
Exempt 2013-004091-34 A randomised Phase II study of Enzalutamide (MDV3100) in combination with AZD5363 in Patients with Metastatic Castration - Resistant Prostate Cancer not-yet-due
Not reported Terminated 2014-000845-64 A multicentre randomised phase II study of aflibercept plus chemotherapy in patients with colorectal liver-only metastases deemed to be inoperable or unsuitable for upfront liver resection 2015-03-10 due-trials
Ongoing 2014-000887-16 A phase II randomised study evaluating the biological and clinical effects of the combination of palbociclib with letrozole as neoadjuvant therapy in post-menopausal women with ER+ primary breast canc... not-yet-due
Ongoing 2014-001470-34 Pilot institutional study evaluating 5-fluorouracil following radiation therapy in children and young adults with relapsed/refractory ependymoma. not-yet-due
Ongoing 2014-003319-12 Window study of the PARP inhibitor rucaparib in patients with primary triple negative or BRCA1/2 related breast cancer (RIO) not-yet-due
Ongoing 2014-004065-25 Randomised Phase II Trial of Pembrolizumab and Radiotherapy in Melanoma not-yet-due
Ongoing 2014-005684-32 [18F] DIHYDRO-TESTOSTERONE PET IMAGING IN PATIENTS WITH PROGRESSIVE PROSTATE CANCER not-yet-due
Ongoing 2015-001605-14 A Randomised, double-blind, placebo controlled, multi-centre phase II study to assess the Efficacy and safety of 2nd line Olaparib in combination with Paclitaxel, in Western patients with advanced gas... not-yet-due
Ongoing 2015-003009-40 Magnetic Resonance Tumour Regression Grade (mrTRG) as a Novel Biomarker to Stratify Management of Good And Poor Responders To Chemoradiotherapy: A Rectal Cancer Multicentre Randomised Control Trial not-yet-due
Ongoing 2015-005525-39 Proof-of-concept study of ibrutinib in c-MYC and HER2 amplified gastrooesophageal carcinoma not-yet-due
Ongoing 2017-000370-10 Avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III dMMR or POLE exonuclease domain mutant colon cancer: A phase III randomised study. not-yet-due
Ongoing 2017-001680-20 Phase II study of ROS1 targeting with crizotinib in advanced E-cadherin negative, ER positive lobular breast cancer or diffuse gastric cancer not-yet-due